CoChat

Randomized Controlled Trial of Mobile Closed-Loop Control

Open access
Kovatchev, Boris, Anderson, Stacey M., Raghinaru, Dan, Kudva, Yogish C., Laffel, Lori M., Levy, Carol, Pinsker, Jordan E., Wadwa, R. Paul, Buckingham, Bruce, Doyle, Francis J., Brown, Sue A., Church, Mei Mei, Dadlani, Vikash, Dassau, Eyal, Ekhlaspour, Laya, Forlenza, Gregory P., Isganaitis, Elvira, Lam, David W., Lum, John, Beck, Roy W., iDCL Study Group, Kovatchev, Boris, Anderson, Stacey M., Brown, Sue A., Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Oliveri, Mary, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc, Laffel, Lori M., Isganaitis, Elvira, Ambler-Osborn, Louise, Flint, Emily, Schultz, Alan, Kim, Kenny, Pinsker, Jordan E., Church, Mei Mei, Andre, Camille, Levy, Carol, Lam, David W., O’Malley, Grenye, Levister, Camilla, Ogyaadu, Selassie, Kudva, Yogish C., Dadlani, Vikash, Simha, Vinaya, McCrady-Spitzer, Shelly, Reid, Corey, Wadwa, R. Paul, Forlenza, Gregory P., Jost, Emily, Messer, Laurel, Berget, Cari, Towers, Lindsey, Buckingham, Bruce, Ekhlaspour, Laya, Hsu, Liana, Loebner, Sarah, Doyle, Francis J., Dassau, Eyal, Lum, John, Beck, Roy W., Campos, Tiffany, Passman, Samantha, Murphy, Carlos, Patibandla, Nandan, Raghinaru, Dan, Kollman, Craig · 2020 · Diabetes Care

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS: This protocol, NCT02985866, is a 3-month parallel-group, multicenter, randomized unblinded trial designed to compare mobile CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ≥14 years, and baseline HbA1c <10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. RESULTS: Between November 2017 and May 2018, 127 participants were randomly assigned 1:1 to CLC (n = 65) versus SAP (n = 62); 125 participants completed the study. CGM time below 3.9 mmol/L was 5.0% at baseline and 2.4% during follow-up in the CLC group vs. 4.7% and 4.0%, respectively, in the SAP group (mean difference −1.7% [95% CI −2.4, −1.0]; P < 0.0001 for superiority). CGM time above 10 mmol/L was 40% at baseline and 34% during follow-up in the CLC group vs. 43% and 39%, respectively, in the SAP group (mean difference −3.0% [95% CI −6.1, 0.1]; P < 0.0001 for noninferiority). One severe hypoglycemic event occurred in the CLC group, which was unrelated to the study device. CONCLUSIONS: In meeting its coprimary end points, superiority of CLC over SAP in CGM-measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L, the study has demonstrated that mobile CLC is feasible and could offer certain usability advantages over embedded systems, provided the connectivity between system components is stable.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc19-1310

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 60

Metadata

Authors
Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., Brown, S. A., Church, M. M., Dadlani, V., Dassau, E., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Lum, J., Beck, R. W., iDCL Study Group, Kovatchev, B., Anderson, S. M., Brown, S. A., Emory, E., Voelmle, M., Conshafter, K., Morris, K., Oliveri, M., Mitchell, H., Calvo, K., Wakeman, C., Breton, M., Laffel, L. M., Isganaitis, E., Ambler-Osborn, L., Flint, E., Schultz, A., Kim, K., Pinsker, J. E., Church, M. M., Andre, C., Levy, C., Lam, D. W., O’Malley, G., Levister, C., Ogyaadu, S., Kudva, Y. C., Dadlani, V., Simha, V., McCrady-Spitzer, S., Reid, C., Wadwa, R. P., Forlenza, G. P., Jost, E., Messer, L., Berget, C., Towers, L., Buckingham, B., Ekhlaspour, L., Hsu, L., Loebner, S., Doyle, F. J., Dassau, E., Lum, J., Beck, R. W., Campos, T., Passman, S., Murphy, C., Patibandla, N., Raghinaru, D., & Kollman, C.
Venue
Diabetes Care
Published
2020-01-14
Volume
43
Issue
3
Pages
607-615
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W3000000785
Cited by
60
References
23
Citations by year
2026: 4 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 8 · 2021: 12 · 2020: 8
FWCI
7.35
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (UC4-DK-108483)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
type 1 diabetes, sensor-augmented pump, continuous glucose monitoring, insulin pump therapy, hypoglycemia, hyperglycemia, glycemic control, non-inferiority
MeSH terms
Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, United States, Blood Glucose Self-Monitoring, Biosensing Techniques, Telemedicine, Pancreas, Artificial, Young Adult, Insulin, Regular, Human, Mobile Applications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Controlled Trial of Mobile Closed-Loop Control. https://app.cochat.ai/papers/10.2337/dc19-1310
The paper
Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., Brown, S. A., Church, M. M., Dadlani, V., Dassau, E., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Lum, J., . . . Kollman, C. (2020). Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care. https://doi.org/10.2337/dc19-1310

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.